The AstraZeneca PLC ADR AZN rose 1.25% to $68.81 Friday, on what proved to be an all-around positive trading session for the ...

The AstraZeneca PLC ADR AZN slipped 2.20% to $66.23 Wednesday, on what proved to be an all-around mixed trading session for ...

Las acciones de las empresas farmacéuticas cayeron en todo el mundo después de que el presidente de EE.UU., Donald Trump, ...

AstraZeneca Plc lost its crown as the UK’s most valuable listed company after US President Donald Trump’s plans to lower drug ...

AstraZeneca PLC is set to release its Q1 2025 earnings on April 29, 2025.The consensus estimate for Q1 2025 revenue is $133.16 billion, and the earnings are expected to come in at $15.74 per share.

Welcome ladies and gentlemen to AstraZeneca's Q1 2025 Results Conference Call for Investors and Analysts. Before I hand over to AstraZeneca, I'd like to read the Safe Harbor Statement. The company ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) ...

Rare Disease Revenue: $2 billion, stable year-on-year. AstraZeneca PLC (NASDAQ:AZN) reported a strong start to 2025 with a 10% increase in total revenue, driven by demand for innovative medicines.

Mereo BioPharma Group plc’s MREO share price has dipped by 5.63%, which has investors questioning if this is right time to ...

Investors in AstraZeneca plc (Symbol: AZN) saw new options become available today, for the June 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AZN ...

AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Call Transcript April 29, 2025 AstraZeneca PLC beats earnings expectations. Reported EPS is $1.3, expectations were $1.1. Andy Barnett - Head of IR ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) has announced positive results from the POTOMAC Phase III trial, which evaluated Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG ...